Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Pancreatology
- Vol. 18 (3) , 313-317
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Consensus Guidelines for the Management and Treatment of Neuroendocrine TumorsPancreas, 2013
- Proportion cured models applied to 23 cancer sites in NorwayInternational Journal of Cancer, 2012
- Relapse-Free Survival in Patients With Nonmetastatic, Surgically Resected Pancreatic Neuroendocrine TumorsAnnals of Surgery, 2012
- The Cure Fraction of Glioblastoma MultiformeNeuroepidemiology, 2012
- Everolimus for Advanced Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine TumorsNew England Journal of Medicine, 2011
- Are There Prognostic Factors Related to Recurrence in Pancreatic Endocrine Tumors?Pancreatology, 2010
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- Improved survival time: What can survival cure models tell us about population‐based survival improvements in late‐stage colorectal, ovarian, and testicular cancer?Cancer, 2008
- Estimating Cure Rates From Survival DataJournal of the American Statistical Association, 2003